Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2

Conditions

Uterine Cervical Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Anus Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 8pembrolizumab 7fludarabine 6aldesleukin 4Papillomavirus Vaccines 4Vaccines 3Radiotherapy 3Light Coagulation 3Biopsy 3spartalizumab 2fludarabine phosphate 2entinostat 2Watchful Waiting 2Vorinostat 2VGX-3100 2Trastuzumab 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Paclitaxel 2Observation 2Nivolumab 2Interleukin-2 2Interleukin-12 Subunit p35 2Early Intervention, Educational 2Drug Therapy 2Carboplatin 2Adoptive Transfer 2trastuzumab deruxtecan 1tislelizumab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anus Neoplasms × Adoptive Transfer × Gynecologic × Clear all
NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers, The State University of New Jersey

Phase 1/2 Recruiting
15 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT05686226 2026-02-27

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Rutgers, The State University of New Jersey

Phase 2 Recruiting
20 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡